The Food and Drug Administration has approved mitomycin pyelocalyceal (Jelmyto), the first therapy for adults with low-grade upper tract urothelial cancer.
"This is the first approval specifically for patients with low-grade [upper tract urothelial cancer] and provides an option for some patients who may otherwise require a nephroureterectomy," Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence, said in a statement.
"Due to substantial treatment challenges associated with the complex anatomy of the upper urinary tract, many patients need to be treated with radical surgery – usually complete removal of the affected kidney, ureter, and bladder cuff," Dr. Pazdur added. "Jelmyto gives patients, for the first time, an alternative treatment option for low-grade [upper tract urothelial cancer]."
The FDA’s approval of mitomycin is based on results from the phase 3 OLYMPUS trial (NCT02793128). This ongoing, single-arm trial enrolled 71 patients with treatment-naive or recurrent low-grade noninvasive upper tract urothelial cancer with at least one measurable papillary tumor located above the ureteropelvic junction. Patients with larger tumors were allowed to have prior tumor debulking.
The patients received mitomycin weekly for 6 weeks at the recommended dose of 4 mg/mL, instilled via ureteral catheter or nephrostomy tube, with the total instillation volume based on volumetric measurements using pyelography, not exceeding 15 mL (60 mg mitomycin).
Patients who achieved a complete response at 3 months could receive monthly instillations up to a maximum of 11 additional instillations.
At 3 months, 41 patients (58%) achieved a complete response (CR). At 12 months after CR determination, 19 patients were still in CR, and 7 patients had documented recurrences. The median duration of CR was not reached.
The most common adverse events (occurring in at least 20% of patients) were ureteric obstruction, flank pain, urinary tract infection, hematuria, renal dysfunction, fatigue, nausea, abdominal pain, dysuria, and vomiting. Ureteric obstruction occurred in 58% of patients, and 88% of those patients required ureteral stent placement.
In all, 23% of patients discontinued mitomycin due to adverse events, and 34% had dose interruptions due to adverse events.
The approval of mitomycin was granted to UroGen Pharma. The FDA granted the application priority review, fast track designation, and breakthrough therapy designation.
The full prescribing information for mitomycin is available for download from the FDA website.
This story originally appeared on MDedge.com.
Cite this: Mitomycin Approved for Low-Grade Upper Tract Urothelial Cancer - Medscape - Apr 16, 2020.